Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice

[1]  A. Yu,et al.  Modification of 5-methoxy-N, N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms , 2016, Pharmacological reports : PR.

[2]  A. Halberstadt.  Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine , 2016, Pharmacology Biochemistry and Behavior.

[3]  Hongbin Sun,et al.  Current developments in pharmacological therapeutics for chronic constipation , 2015, Acta pharmaceutica Sinica. B.

[4]  A. Yu,et al.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors , 2015, Neuropharmacology.

[5]  K. Rahmouni,et al.  The brain and brown fat , 2014, Annals of medicine.

[6]  S. Zorn,et al.  Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats , 2014, Neuropharmacology.

[7]  John M. Johnson,et al.  Cutaneous vasodilator and vasoconstrictor mechanisms in temperature regulation. , 2014, Comprehensive Physiology.

[8]  Š. Alušík,et al.  Serotonin syndrome. , 2014, Neuro endocrinology letters.

[9]  R. Tyndale,et al.  Potential role of CYP2D6 in the central nervous system , 2013, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  D. Mager,et al.  Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status , 2013, Drug Metabolism and Disposition.

[11]  E. Liebelt,et al.  Recognizing Serotonin Toxicity in the Pediatric Emergency Department , 2012, Pediatric emergency care.

[12]  R. Bruno,et al.  Emerging psychoactive substance use among regular ecstasy users in Australia. , 2012, Drug and alcohol dependence.

[13]  A. Bortolozzi,et al.  Acute 5-HT1A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions , 2012, Psychopharmacology.

[14]  D. E. Nichols,et al.  Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor , 2012, Psychopharmacology.

[15]  M. Geyer,et al.  Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice , 2011, Journal of psychopharmacology.

[16]  J. C. Winter,et al.  Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice , 2011, Pharmacology Biochemistry and Behavior.

[17]  Adam L. Halberstadt,et al.  Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens , 2011, Neuropharmacology.

[18]  S. Morrison,et al.  Central efferent pathways for cold‐defensive and febrile shivering , 2011, The Journal of physiology.

[19]  Hong-Wu Shen,et al.  Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice , 2011, Drug Metabolism and Disposition.

[20]  Jeremy Terrien,et al.  Behavioral thermoregulation in mammals: a review. , 2011, Frontiers in bioscience.

[21]  A. Yu,et al.  Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. , 2010, Biochemical pharmacology.

[22]  P. Gillman.  Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. , 2010, Headache.

[23]  A. Yu,et al.  Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. , 2009, Biochemical pharmacology.

[24]  B. Olivier,et al.  Pharmacological characterization of harmaline-induced tremor activity in mice. , 2009, European journal of pharmacology.

[25]  M. Baumert,et al.  Blockade of 5-HT2A receptors suppresses hyperthermic but not cardiovascular responses to psychosocial stress in rats , 2009, Neuroscience.

[26]  M. Geyer,et al.  Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors , 2008, Psychopharmacology.

[27]  A. Yu.  Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions , 2008, The AAPS Journal.

[28]  A. Yuruktumen,et al.  Syrian rue tea: A recipe for disaster , 2008, Clinical toxicology.

[29]  M. Zaretskaia,et al.  3,4-Methylenedioxymethamphetamine- and 8-Hydroxy-2-di-n-propylamino-tetralin-Induced Hypothermia: Role and Location of 5-Hydroxytryptamine 1A Receptors , 2007, Journal of Pharmacology and Experimental Therapeutics.

[30]  C. Villalón,et al.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

[31]  Xiaoning Wang,et al.  Nonlinear random effects mixture models: Maximum likelihood estimation via the EM algorithm , 2007, Comput. Stat. Data Anal..

[32]  Henrik Madsen,et al.  PKPD Model of Interleukin-21 Effects on Thermoregulation in Monkeys—Application and Evaluation of Stochastic Differential Equations , 2007, Pharmaceutical Research.

[33]  Y. Ootsuka,et al.  Thermogenesis in brown adipose tissue: Increase by 5-HT2A receptor activation and decrease by 5-HT1A receptor activation in conscious rats , 2006, Neuroscience Letters.

[34]  D. Rusyniak,et al.  Hyperthermic syndromes induced by toxins. , 2006, Clinics in laboratory medicine.

[35]  L. Peletier,et al.  A Pharmacodynamic Turnover Model Capturing Asymmetric Circadian Baselines of Body Temperature, Heart Rate and Blood Pressure in Rats: Challenges in Terms of Tolerance and Animal-handling Effects , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[36]  B. Levine,et al.  A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. , 2005, Journal of analytical toxicology.

[37]  Amy E. Miller,et al.  Evaluation of Herbal Dietary Supplements Marketed on the Internet for Recreational Use , 2005, The Annals of pharmacotherapy.

[38]  M. Tariq,et al.  Exacerbation of harmaline-induced tremor by imipramine , 2005, Pharmacology Biochemistry and Behavior.

[39]  Mats O Karlsson,et al.  Pharmacokinetic/pharmacodynamic modelling in oncological drug development. , 2005, Basic & clinical pharmacology & toxicology.

[40]  D. Murphy,et al.  Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors , 2005, Psychopharmacology.

[41]  T. Ullrich,et al.  Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine , 2005, Psychopharmacology.

[42]  P. Bonaventure,et al.  8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. , 2004, European journal of pharmacology.

[43]  L. Peletier,et al.  Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats , 2004, Journal of Pharmacology and Experimental Therapeutics.

[44]  E. Boyer,et al.  Monoamine Oxidase Inhibitor Poisoning Resulting from Internet Misinformation on Illicit Substances , 2004, Journal of toxicology. Clinical toxicology.

[45]  W. Löscher,et al.  Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia , 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

[46]  D. Spencer,et al.  Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine , 2004, Psychopharmacology.

[47]  R. Glennon,et al.  Binding of β-Carbolines at 5-HT2 serotonin receptors , 2003 .

[48]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[49]  Tommy Pattij,et al.  Stress-induced hyperthermia and anxiety: pharmacological validation. , 2003, European journal of pharmacology.

[50]  J. Idle,et al.  The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. , 2001, Molecular pharmacology.

[51]  P H van der Graaf,et al.  A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[52]  J. Ott.  Pharmepéna-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine , 2001, Journal of psychoactive drugs.

[53]  P. Salmi,et al.  Evidence for functional interactions between 5-HT1A and 5-HT2A receptors in rat thermoregulatory mechanisms. , 1998, Pharmacology & toxicology.

[54]  Kinzo Matsumoto,et al.  Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline- and harmaline-pretreated rats. , 1997, General pharmacology.

[55]  B. Roth,et al.  High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. , 1997, The Journal of pharmacology and experimental therapeutics.

[56]  R. Ramsay,et al.  Inhibition of Monoamine Oxidase A by β-Carboline Derivatives , 1997 .

[57]  D. Goldstein,et al.  Stress-induced activation of the sympathetic nervous system. , 1987, Bailliere's clinical endocrinology and metabolism.